Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Neoplasms 3Motor Activity 2Smoking Cessation 1Smoking 1Neurocognitive Disorders 1Multiple Endocrine Neoplasia Type 1 1Leukemia 1Hematologic Neoplasms 1Graft vs Host Disease 1Depression 1Cognitive Dysfunction 1Chronic Disease 1Breast Carcinoma In Situ 1

Interventions

Cyclophosphamide 344Cytarabine 281fludarabine phosphate 201Methotrexate 185Filgrastim 159Busulfan 147Etoposide 135Peripheral Blood Stem Cell Transplantation 133fludarabine 127Rituximab 119Radiotherapy 111Vincristine 102Cyclosporine 98Daunorubicin 96Antilymphocyte Serum 94Dexamethasone 91Tacrolimus 85Mycophenolic Acid 85Whole-Body Irradiation 80Melphalan 79Idarubicin 67Mercaptopurine 66Imatinib Mesylate 66Granulocyte Colony-Stimulating Factor 65Azacitidine 65Methylprednisolone 59Prednisone 58Doxorubicin 58Clofarabine 54sargramostim 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Leukemia × Health × Clear all
NCT02976558 2019-12-18

TriCAM

University of Erlangen-Nürnberg Medical School

Phase NA Terminated
104 enrolled
Other hematologic neoplasm

Depression, Graft vs Host Disease, Leukemia, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡